Comparative Pharmacology
Head-to-head clinical analysis: DRIXORAL versus EFIDAC 24 CHLORPHENIRAMINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRIXORAL versus EFIDAC 24 CHLORPHENIRAMINE MALEATE.
DRIXORAL vs EFIDAC 24 CHLORPHENIRAMINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Drixoral is a combination product containing dexbrompheniramine maleate, a first-generation antihistamine that competitively antagonizes histamine at H1 receptor sites, and pseudoephedrine sulfate, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
Chlorpheniramine maleate is a first-generation alkylamine antihistamine that competitively antagonizes histamine at H1 receptor sites, preventing histamine-mediated allergic reactions. It also has anticholinergic and sedative properties due to central H1 receptor blockade.
One pseudoephedrine 60 mg and dexbrompheniramine 2 mg tablet orally every 12 hours; maximum 2 tablets per 24 hours.
4 mg orally every 4-6 hours; maximum 24 mg/day.
None Documented
None Documented
Dexbrompheniramine: 12-15h (prolonged in renal impairment). Pseudoephedrine: 5-8h (alkaline urine slows elimination, half-life up to 20h).
Terminal elimination half-life ranges from 14 to 25 hours (mean 20 hours) in adults; prolonged in hepatic or renal impairment (up to 50-60 hours in cirrhosis).
Drixoral contains dexbrompheniramine (renal: 30-50% unchanged, rest metabolites) and pseudoephedrine (renal: 70-90% unchanged, pH-dependent).
Renal excretion of unchanged drug and metabolites accounts for approximately 70-80% of elimination, with about 20-30% excreted via feces (biliary).
Category C
Category C
Antihistamine/Decongestant
Antihistamine